Malignant neoplasm of stomach. Malignant neoplasm of stomach
Conditions
Interventions
All study participants undergo XELIRINOX regimen which will need to be repeated every 3 weeks up to a total of 6 cycles (irinotecan 180 mg/m2 intra-arterial injection on day 1, intraarterial oxaliplat
Treatment - Drugs
Sponsors
Hematology-Oncology & Stem Cell Research Center
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: All patients with metastatic gastric cancer who have not previously received any chemotherapy; All patients with metastatic gastric cancer without an appropriate response to previous treatments; signing informed consent form; have a life expectancy of at least 12 weeks; Patients who can be followed up. Exclusion criteria:Patients who have non metastatic gastric cancer; Patients who have a debilitating underlying disease; Patients who develop complications during treatment due to chemotherapy or gastric cancer.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response to Treatment. Timepoint: 3 and 6 weeks after stat treatment. Method of measurement: using Response Evaluation Criteria in Solid Tumors (RECIST). | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival. Timepoint: One year after start treatment. Method of measurement: Follow-up Patient.;Progression-free Survival. Timepoint: 12 months after start treatment. Method of measurement: Patient Follow-up Visit to Assess the Progress of the Disease by CT Scan. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.saeed Anvari
Hematology-Oncology & Stem Cell Research Center
Outcome results
None listed